Revolutionizing Ocular Surface Disease Treatment: TearSolutions Secures $3 Million in Series B Funding

TearSolutions Inc., a groundbreaking Delaware Corporation based in Charlottesville, VA, has announced an impressive $3 million in funding to further advance its innovative treatment for ocular surface disease, particularly in patients with primary Sjögren’s Syndrome. This round of funding follows the successful completion of a Phase II Proof of Concept clinical trial with 204 patients, where remarkable and statistically significant improvements were observed in key signs and symptoms of dry eye within just two weeks. The trial evaluated the efficacy of Lacripep™, a novel 19 amino acid peptide, which is found in normal tears but deficient in individuals suffering from dry eye disorders. By restoring homeostasis to the ocular surface and enhancing the barrier function of the corneal epithelium, Lacripep™ demonstrates significant potential as a leading therapeutic option. The funding will support further clinical development and the regulatory pathway for Lacripep™, enabling the company to build on the promising results observed in their trials. The management team, comprised of experienced professionals including CEO Anil Asrani and CSO Dr. Gordon W. Laurie, is focused on expanding the company's mission to revolutionize the treatment landscape for dry eye, a condition that represents a significant unmet medical need. Lacripep™ was originally discovered at the University of Virginia, highlighting a robust pipeline of scientific research. Additionally, the company aims to leverage this financial momentum to refine their clinical strategies and move closer to obtaining FDA approval. For further insights into their groundbreaking work, please visit www.tearsolutions.com.